Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

tion has occurred. Consolidation or financial difficulties could cause customers to reduce their inventory levels, or otherwise reduce purchases of the Group's products. Such actions could have an adverse effect on the Group's revenues, financial condition and results of operations. A significant portion of the Group's Specialty Pharmaceuticals product sales are made to major pharmaceutical wholesale distributors as well as to large pharmacies in both the US and Europe. Consequently, product sales and growth comparisons may be affected by fluctuations in the buying patterns of major distributors and other trade buyers. These fluctuations may result from seasonality, pricing, wholesaler buying decisions, or other factors. In addition, a significant portion of the Group's revenues for certain products for treatment of rare genetic diseases are concentrated with a small number of customers. Changes in the buying patterns of those customers may have an adverse effect on the Group's financial condition and results of operations.

The outsourcing of services can create a significant dependency on third parties, the failure of whom can affect the ability to operate the Group's business and to develop and market products

The Group has entered into many agreements with third parties for the provision of services to enable it to operate its business. If the third party can no longer provide the service on the agreed basis, the Group may not be able to continue the development or commercialization of its products as planned or on a commercial basis. Additionally, it may not be able to establish or maintain good relationships with the suppliers.

The Group has also entered into licensing and co-development agreements with a number of parties. There is a risk that, upon expiration or termination of a third party agreement, the Group may not be able to renew or extend the agreement with the third party as commercial
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that ... in its catalogue: Global Biodegradable ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable ... are readily decomposed by the action of ... packaging in terms of raw materials, production ...
(Date:8/27/2014)... Dallas, TX (PRWEB) August 27, 2014 ... professional and in-depth study on the current state of ... The report provides a basic overview of the industry, ... analysis and Chinese domestic market analysis are provided with ... of the market. A comparison between the international and ...
(Date:8/27/2014)... Aug. 27, 2014  Lisa Kulik saw fireworks for ... 4 holiday, thanks to a groundbreaking retinal implant co-invented ... renowned clinician-researcher at the University of Southern California (USC) ... Peoria, Ariz. resident who has retinitis ... of sight. On June 2, she became the first ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5
... global,specialty biopharmaceutical company announces results for the year to,December 31, 2008 - a year which has seen significant ... ... Q4 2008 (1), Product sales ... 27% $0.70 bn + 7%(3), Product sales, ...
... NEWARK, Del., Feb. 19 Lightwave Logic, Inc. (OTC ... technology company focused on the development of electro-optic polymer ... optical computing, announced today the addition of Anthony J. ... for 30 years in medicinal chemistry and brings a ...
... most widely used drugs, is also one of the trickiest ... risk of serious problems when given the standard starting dose. ... medicine" based on genetic information, an international research team has ... of the blood-thinning drug for each patient. , Three ...
Cached Biology Technology:Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 2Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 3Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 4Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 5Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 6Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 7Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 8Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 9Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 10Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 11Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 12Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 13Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 14Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 15Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 16Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 17Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 18Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 19Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 20Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 21Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 22Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 23Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 24Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 25Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 26Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 27Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 28Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 29Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 30Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 31Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 32Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 33Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team 2Genetic information personalizes warfarin prescribing 2Genetic information personalizes warfarin prescribing 3
(Date:8/28/2014)... have identified a handful of bacterial culprits that may ... and ulcerative colitis, using patients, own intestinal immune responses ... 28 in the journal Cell . , Trillions ... plays a critical role in the development and progression ... number of bacterial species affect a person,s susceptibility to ...
(Date:8/28/2014)... and his collaborators have developed an online analytic tool ... re-engineering cells for biomedical investigation. CellNet is a free-use ... stem cell engineering. Details of CellNet and its application ... papers in the journal Cell . , "This ... all types of cell-based investigations and can potentially offer ...
(Date:8/28/2014)... 2014  Privacy Advocate and Senior Staff Attorney at ... joins the lineup of biometric and mobile commerce experts ... Executive Summit in Tampa, Florida ... speakers include Steven Rahman, Director, Technology and Strategy at Samsung, ... The theme of this year,s event is Mobility at ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2New tool aids stem cell engineering for medical research 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... do not increase their life expectancy by taking the ... from UC Davis, UCSF, the University of Pittsburgh and ... showed that tamoxifen is an extraordinarily expensive cancer-prevention strategy, ... life saved. The study will be published in the ...
... specific cell protein can trigger the spread of cancer. The ... Edinburgh Cancer Research Centre could pave the way for new ... cell cancerous. , The protein, MDM2, normally functions to ... p53. In some of the body's cells, the biochemical ratio ...
... field surveys of the Rubeho Mountains in Tanzania ... of frog and eleven endemic species--according to an ... this month. The findings elevate the importance of ... Eastern Arc Mountain range from destructive activities underway ...
Cached Biology News:Tamoxifen for breast cancer prevention does not benefit most women 2Tamoxifen for breast cancer prevention does not benefit most women 3First surveys of Tanzanian mountains reveal 160+ animal species, including new & endemic 2
... c-Jun N-terminal kinase (JNK) is one of ... luciferase has been used as a sensitive ... Luciferase provides a 1000-fold increase in sensitivity ... (CAT) assay. Firefly luciferase catalyzes the oxidative ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: filling ...
... Linkage: This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... DMEM and harvested at the log phase of ... in their native forms, cells were fixed in ... 12-well (5 mm) adhesive coated slide, with each ... and to minimize background staining. Each well ...
Biology Products: